Your browser is no longer supported. Please, upgrade your browser.
Settings
BDSI BioDelivery Sciences International, Inc. daily Stock Chart
BDSI [NASD]
BioDelivery Sciences International, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own5.40% Shs Outstand58.43M Perf Week4.35%
Market Cap140.23M Forward P/E- EPS next Y-0.38 Insider Trans-23.84% Shs Float53.70M Perf Month14.29%
Income-53.70M PEG- EPS next Q-0.18 Inst Own48.00% Short Float5.51% Perf Quarter14.29%
Sales43.80M P/S3.20 EPS this Y107.50% Inst Trans2.63% Short Ratio7.70 Perf Half Y2.13%
Book/sh0.02 P/B120.00 EPS next Y46.80% ROA-61.60% Target Price4.58 Perf Year9.09%
Cash/sh0.21 P/C11.59 EPS next 5Y25.00% ROE-388.40% 52W Range1.70 - 3.60 Perf YTD-18.64%
Dividend- P/FCF- EPS past 5Y11.70% ROI24.50% 52W High-33.33% Beta0.52
Dividend %- Quick Ratio1.10 Sales past 5Y2.60% Gross Margin60.60% 52W Low41.18% ATR0.17
Employees115 Current Ratio1.40 Sales Q/Q-61.70% Oper. Margin- RSI (14)61.93 Volatility8.40% 8.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-121.20% Profit Margin- Rel Volume1.75 Prev Close2.50
ShortableYes LT Debt/Eq34.50 EarningsMay 10 AMC Payout- Avg Volume383.93K Price2.40
Recom1.60 SMA2017.65% SMA5014.70% SMA200-5.80% Volume672,648 Change-4.00%
Jan-26-18Initiated Seaport Global Securities Buy $5
Aug-14-17Resumed Cantor Fitzgerald Overweight $4.50
Aug-10-17Reiterated H.C. Wainwright Buy $4 → $5
May-26-17Initiated H.C. Wainwright Buy $4
May-17-17Upgrade Cantor Fitzgerald Neutral → Overweight
May-12-16Reiterated Piper Jaffray Overweight $6 → $4
May-11-16Downgrade Cantor Fitzgerald Buy → Hold
May-04-16Reiterated FBR Capital Outperform $12 → $9
Mar-14-16Reiterated Laidlaw Buy $17 → $11
Mar-11-16Reiterated FBR Capital Outperform $13 → $12
Feb-08-16Initiated Piper Jaffray Overweight
Nov-10-15Reiterated FBR Capital Mkt Perform $17 → $14
Nov-04-15Initiated Cantor Fitzgerald Buy
May-12-15Reiterated Cantor Fitzgerald Buy $17 → $12
May-11-15Reiterated ROTH Capital Buy $16 → $14
Apr-22-15Resumed Piper Jaffray Overweight
Apr-02-15Initiated FBR Capital Outperform $19
Mar-31-15Reiterated ROTH Capital Buy $18 → $16
Dec-19-14Upgrade ROTH Capital Neutral → Buy $20 → $18
Oct-10-14Downgrade ROTH Capital Buy → Hold $20
May-23-18 08:00AM  BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 02:02PM  BDSI closes $50M equity financing heres what its board looks like now American City Business Journals
08:29AM  BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board GlobeNewswire
May-17-18 09:00AM  Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE +17.95%
08:01AM  BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business GlobeNewswire
08:01AM  BioDelivery Sciences Announces Pricing of $50 Million Equity Financing GlobeNewswire
May-13-18 11:51AM  Edited Transcript of BDSI earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-11-18 09:27AM  BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates Zacks
May-10-18 04:11PM  BioDelivery: 1Q Earnings Snapshot Associated Press
04:01PM  BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:36PM  Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings Zacks
May-08-18 06:24PM  What's in Store for Endocyte (ECYT) This Earnings Season? Zacks
11:31AM  BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect? Zacks
May-07-18 09:00AM  BioDelivery Sciences Appoints Herm Cukier as Chief Executive Officer GlobeNewswire
May-03-18 09:01AM  BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital GlobeNewswire
Apr-30-18 07:00AM  BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10 GlobeNewswire
Apr-19-18 08:25AM  Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-16-18 03:16AM  Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report? Zacks
Apr-03-18 08:36AM  From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018 American City Business Journals
Mar-21-18 08:42AM  BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher Zacks
07:20AM  Blog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong ACCESSWIRE
Mar-16-18 11:24AM  BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y Zacks
11:21AM  Edited Transcript of BDSI earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
08:25AM  Raleigh pharma quadruples revenue, lands new contract American City Business Journals
Mar-15-18 04:37PM  CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update GlobeNewswire -6.82%
04:37PM  BioDelivery reports 4Q loss Associated Press
04:01PM  BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:45PM  BioDelivery Sciences International, Inc. to Host Earnings Call ACCESSWIRE
09:02AM  What You Must Know About BioDelivery Sciences International Incs (NASDAQ:BDSI) ROE Simply Wall St.
Mar-14-18 07:00AM  BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-07-18 07:00AM  BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15 GlobeNewswire
Mar-05-18 07:00AM  BioDelivery Sciences to Present at the 30th Annual ROTH Conference GlobeNewswire
Mar-01-18 08:40AM  What's in the Cards for BioDelivery (BDSI) in Q4 Earnings? Zacks
Feb-28-18 12:55PM  Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4 Zacks
Feb-16-18 03:16PM  United Therapeutics settles patent litigation over $157M drug American City Business Journals
Feb-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Programs and Systems New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-18 08:35AM  BDSI reaches settlement with generic drug giant Teva American City Business Journals
Feb-06-18 07:00AM  BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva GlobeNewswire
Jan-30-18 08:00AM  BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada GlobeNewswire
08:00AM  BELBUCA® - A New Treatment Option for Canadians Living With Chronic Pain - Now Available in Canada CNW Group
Jan-04-18 08:00AM  Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development Marketwired
Jan-01-18 09:19AM  BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-22-17 12:50PM  BDSIs new president: We're expanding our sales force American City Business Journals
Dec-20-17 08:45AM  BioDelivery Sciences Appoints Scott Plesha to President GlobeNewswire
Dec-18-17 07:00AM  BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032 GlobeNewswire
Dec-14-17 04:31PM  BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical GlobeNewswire -6.25%
Nov-27-17 07:00AM  BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary PR Newswire
Nov-20-17 08:15AM  Market Trends Toward New Normal in OneMain, Versum Materials, BioDelivery Sciences International, Microsemi, Pattern Energy Group, and Omega Protein Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-16-17 07:00AM  BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference PR Newswire
Nov-13-17 10:21AM  Edited Transcript of BDSI earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 04:29PM  BioDelivery reports 3Q loss Associated Press
04:01PM  BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
12:35PM  Is BioDelivery Sciences International Incs (BDSI) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
10:10AM  BioDelivery Sciences International, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 09:47AM  BioDelivery (BDSI) to Report Q3 Earnings: What's in Store? Zacks
Nov-03-17 05:15PM  Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI) PR Newswire
Nov-02-17 11:52AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc. Business Wire
Oct-31-17 10:12AM  Penny Stocks to Watch for November 2017 Investopedia
Oct-30-17 11:27AM  ETFs with exposure to BioDelivery Sciences International, Inc. : October 30, 2017 Capital Cube
07:00AM  BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9 PR Newswire
Oct-20-17 10:06AM  ETFs with exposure to BioDelivery Sciences International, Inc. : October 20, 2017 Capital Cube +5.36%
Oct-12-17 02:30PM  BDSI settles patent litigation with generic giant Teva American City Business Journals
07:00AM  BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva PR Newswire
Oct-09-17 11:18AM  ETFs with exposure to BioDelivery Sciences International, Inc. : October 9, 2017 Capital Cube
Oct-06-17 07:00AM  BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence PR Newswire
Sep-28-17 10:09AM  ETFs with exposure to BioDelivery Sciences International, Inc. : September 28, 2017 Capital Cube
Sep-27-17 09:05AM  BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017 Capital Cube
Sep-19-17 07:00AM  BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference PR Newswire
Sep-12-17 08:00AM  BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment PR Newswire
Sep-07-17 08:00AM  BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference PR Newswire
Aug-25-17 07:30AM  Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman ACCESSWIRE
Aug-24-17 11:55AM  BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End Zacks
07:30AM  BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference PR Newswire
Aug-23-17 04:44PM  BDSI CEO to retire American City Business Journals
07:30AM  BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman PR Newswire
Aug-17-17 07:00AM  BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017 PR Newswire
Aug-16-17 10:21PM  Edited Transcript of BDSI earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:10AM  Today's Research Reports on Stocks to Watch: Portola Pharmaceuticals and BioDelivery Sciences International ACCESSWIRE
Aug-10-17 10:20AM  BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls Zacks -6.35%
Aug-09-17 09:29PM  BioDelivery reports 2Q loss Associated Press
04:01PM  BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
12:30PM  Investor Network: BioDelivery Sciences International, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 11:19PM  What's in Store for BioDelivery (BDSI) This Earnings Season? Zacks
04:19PM  ETFs with exposure to BioDelivery Sciences International, Inc. : August 7, 2017 Capital Cube
Jul-31-17 07:00AM  BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update PR Newswire
Jul-28-17 09:27AM  /C O R R E C T I O N -- BioDelivery Sciences International, Inc./ PR Newswire
Jul-14-17 07:50AM  Corporate News Blog - BioDelivery Sciences Collaborates with Canada's Purdue Pharma for Exclusive Distribution, Marketing, and Sale of BELBUCA(R) Accesswire +8.93%
Jul-13-17 06:03PM  BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug Zacks
Jul-12-17 07:30AM  BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA® In Canada PR Newswire
07:30AM  BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) for the Licensing and Distribution Rights of BELBUCA® in Canada CNW Group
Jul-06-17 01:44PM  ETFs with exposure to BioDelivery Sciences International, Inc. : July 6, 2017 Capital Cube
Jun-23-17 04:50PM  Raleigh's BDSI expands international distribution of Belbuca American City Business Journals
07:00AM  BioDelivery Sciences Announces Health Canada Approval of BELBUCA® PR Newswire
Jun-22-17 03:25PM  ETFs with exposure to BioDelivery Sciences International, Inc. : June 22, 2017 Capital Cube
10:08AM  BioDelivery Inks New Contract with CVS/Caremark, Shares Up Zacks
Jun-21-17 02:50PM  Raleigh's BDSI lands CVS/Caremark contract American City Business Journals +5.77%
08:48AM  BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020 PR Newswire
Jun-15-17 03:57AM  BioDelivery Sciences (BDSI) Up 16.7% Since Earnings Report: Can It Continue? Zacks
Jun-14-17 09:36AM  BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-01-17 07:49AM  BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference PR Newswire
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sirgo Mark ADirectorApr 10Sale2.06100,000206,0002,499,542Apr 13 07:02 PM
De Paolantonio Ernest RobertCFO, Secretary and TreasurerApr 06Sale2.0633,25568,505156,709Apr 06 06:01 PM
De Paolantonio Ernest RobertCFO, Secretary and TreasurerApr 05Sale2.1230,90065,508189,864Apr 06 06:01 PM
De Paolantonio Ernest RobertCFO, Secretary and TreasurerApr 03Option Exercise0.00123,1330220,864Apr 06 06:01 PM
Plesha Scott M.PresidentMar 20Option Exercise0.008,3330150,031Mar 22 06:01 PM
ODONNELL FRANCIS E JRDirectorMar 08Option Exercise0.00133,3330451,840Mar 09 06:01 PM
ODONNELL FRANCIS E JRDirectorMar 08Sale2.1466,666142,665385,174Mar 09 06:01 PM
ODONNELL FRANCIS E JRDirectorMar 07Option Exercise0.0094,4180365,717Mar 09 06:01 PM
ODONNELL FRANCIS E JRDirectorMar 07Sale2.1347,210100,557318,507Mar 09 06:01 PM
Plesha Scott M.PresidentMar 01Option Exercise0.0011,6670141,698Mar 02 05:31 PM
Sirgo Mark ADirectorJan 19Sale2.6084,800220,4802,300,661Jan 19 07:05 PM
Sirgo Mark ADirectorJan 18Option Exercise0.00266,66702,460,661Jan 19 07:05 PM
Sirgo Mark ADirectorJan 18Sale2.5875,200194,0162,385,461Jan 19 07:05 PM
Sirgo Mark ADirectorJan 17Option Exercise0.00188,50402,301,994Jan 19 07:05 PM
Sirgo Mark ADirectorJan 17Sale2.57108,000277,5602,193,994Jan 19 07:05 PM
Sirgo Mark ADirectorJan 04Sale2.85278,993795,1302,113,490Jan 19 07:05 PM
Sirgo Mark ADirectorJan 03Sale2.78162,509451,7752,392,483Jan 19 07:05 PM
Sirgo Mark ADirectorJan 02Option Exercise0.001,045,73002,554,992Jan 19 07:05 PM
SEARS SAMUEL P JRDirectorNov 15Sale2.2512,00027,00082,863Nov 17 05:00 PM
Sirgo Mark APresident and CEOSep 21Sale2.756191,7021,509,262Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 20Option Exercise2.3659,265139,7641,575,286Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 20Sale2.7565,405179,8641,509,881Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 19Option Exercise2.0113,66127,4591,540,537Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 19Sale2.7524,51667,4191,516,022Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 18Sale2.856,00017,1001,526,876Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 15Option Exercise1.8678,447145,5801,587,709Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 15Sale2.9054,833159,0161,532,876Sep 22 05:31 PM
Sirgo Mark APresident and CEOSep 14Sale2.9550,000147,5001,509,262Sep 22 05:31 PM
TYSON TIMOTHYDirectorAug 14Option Exercise0.003,65804,658Aug 16 06:15 PM
Bramlage CharlesDirectorAug 14Option Exercise0.0030,000083,150Aug 16 06:12 PM
Feinberg Barry IDirectorAug 14Option Exercise0.0030,000098,500Aug 16 06:08 PM
STONE WILLIAM BDirectorAug 14Option Exercise0.0035,0000159,175Aug 16 06:07 PM
D'Alonzo ThomasDirectorAug 14Option Exercise0.0030,0000161,379Aug 16 06:04 PM
SEARS SAMUEL P JRDirectorAug 14Option Exercise0.0030,000094,863Aug 16 06:02 PM